A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Article 2009 en
Authors
MP
Marc A. Pfeffer
EB
Emmanuel A. Burdmann
CC
Chao Yin Chen
Abstract
1 min read
The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event or death or a renal event) and was associated with an increased risk of stroke. For many persons involved in clinical decision making, this risk will outweigh the potential benefits. (ClinicalTrials.gov number, NCT00093015.)
Scott D. Solomon, Hajime Uno, Eldrin F. Lewis, Kai‐Uwe Eckardt, Julie Lin, Emmanuel A. Burdmann, Dick de Zeeuw, Peter Ivanovich, Andrew S. Levey, Patrick S. Parfrey, Giuseppe Remuzzi, Ajay Singh, Robert D. Toto, Fannie Huang, Jérôme Rossert, John J.V. McMurray, Marc A. Pfeffer
Hicham Skali, Julie Lin, Marc A. Pfeffer, Chaoyin Chen, Mark E. Cooper, John J.V. McMurray, Allen R. Nissenson, Giuseppe Remuzzi, Patrick S. Parfrey, Nairne Scott‐Douglas, Ajay Singh
Karl Swedberg, James B. Young, Inder S. Anand, Sunfa Cheng, Akshay S. Desai, Rafael Díaz, Aldo Maggioni, John J.V. McMurray, Christopher O’Connor, Marc A. Pfeffer, Scott D. Solomon, Yan Sun, Michał Tendera, Dirk J. van Veldhuisen
Akshay S. Desai, Henry Krum, Changhong Yu, Scott M. Wasserman, Eduard Apetrei, Vijay Chopra, Mareev VIu, Aldo Maggioni, John J.V. McMurray, Marc A. Pfeffer, Karl Swedberg, James B. Young
Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L. Bakris, Melanie Chin, Heidi Christ‐Schmidt, Angie Goldsberry, Mark T. Houser, Melissa Krauth, Hiddo J.L. Heerspink, John J.V. McMurray, Colin J. Meyer, Hans‐Henrik Parving, Giuseppe Remuzzi, Robert D. Toto, Nosratola D. Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M. Chertow
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.